Introduction {#s1}
============

The Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) study was a large randomised trial that compared warfarin and rivaroxaban, a novel factor Xa inhibitor, in patients with non-valvular AF, defined as the absence of mitral stenosis or artificial valve prosthesis.[@R1] [@R2] These criteria allowed for the inclusion of patients with other valve disease types, representing a heterogeneous group with mitral regurgitation (MR), aortic regurgitation (AR) or aortic stenosis (AS), alone or in combination.[@R3] The clinical characteristics and outcomes of patients with AF with valve disease, compared with those without, were recently reported.[@R3]

In our retrospective study, we compared the characteristics and outcomes of patients with ROCKET AF without valve disease ('true' non-valvular AF) with two subgroups with valve disease. We hypothesised that patients with AS on oral anticoagulation might have different outcomes than patients with MR or AR.

Methods {#s2}
=======

We used ROCKET AF data to retrospectively perform our analysis.[@R1] [@R2] The rationale and design of ROCKET AF have been previously published (ClinicalTrials.gov \#NCT00403767).[@R1] Our study differed from the previously published analysis[@R3] since we compared two subgroups of patients with valve disease with patients with non-valvular AF. If the recruiting physician considered a lesion to be significant, then the patient was included in the group with significant valve disease (SVD). Patients were excluded if they met clinical criteria for imminent surgical or percutaneous valvular intervention, therefore excluding those with advanced/high-grade valvular disease. Patients with SVD were subdivided into those with AS (if at least one valve location/abnormality was AS) and those with MR or AR ([table 1](#HEARTJNL2015308120TB1){ref-type="table"}), which included patients in whom at least one valve location/abnormality was MR or AR (but none was AS). For the purposes of this study, we analysed patients with: (1) no SVD and subgroups with SVD, (2) AS and (3) MR or AR.

###### 

Location of valvular disease in those 1940 randomised ITT patients in whom information on the location of diseased valves was available

  Type of valve disease                     N
  ----------------------------------------- ------
  Aortic stenosis (n=214)                   
  Isolated aortic stenosis                  87
   Plus mitral regurgitation                59
   Plus aortic regurgitation                18
   Plus mitral and aortic regurgitation     50
  Mitral or aortic regurgitation (n=1726)   
   Isolated mitral regurgitation            1309
   Mitral and aortic regurgitation          329
   Isolated aortic regurgitation            88

ITT, intention to treat.

Among 14 171 intention-to-treat patients, 12 179 had no SVD, whereas 1992 (14.1%) had investigator-classified SVD. In 52 patients with SVD, the valve location was unknown; consequently, they were omitted from the current efficacy analyses, leaving 1940 intention-to-treat patients with SVD (AS, n=214; MR or AR, n=1726). The safety population consisted of 14 236, including 1945 patients with SVD with known location, 12 237 without SVD and 54 patients were omitted for SVD with unknown location.

The primary efficacy endpoint in ROCKET AF was the composite of all stroke (both ischaemic and haemorrhagic) and systemic embolism.[@R1] [@R2] Secondary efficacy endpoints included stroke; all-cause death; the composite of stroke, systemic embolism or vascular death; and the composite of stroke, systemic embolism, vascular death or myocardial infarction. The primary safety endpoint was major or non-major clinically relevant bleeding (NMCR); secondary safety endpoints were major bleeding, gastrointestinal bleeding and intracranial haemorrhage. All clinical endpoints were adjudicated by a committee blinded to the treatment assignment.

Statistical analysis {#s2a}
--------------------

Two populations were used: (1) intention to treat: patients who were randomised, for baseline summaries and analysis of efficacy endpoints and (2) on-treatment (or safety): intention-to-treat patients who received at least one study drug dose, for safety endpoint analysis. The methodology of the present analyses has been reported[@R3] (see online supplementary material).

Clinical characteristics are presented using medians (with 25th and 75th percentiles) for continuous variables and percent (frequency) for categorical variables. A single overall test (Kruskal--Wallis for continuous variables and Pearson χ^2^ for categorical) was performed to determine the differences among the three subgroups.

Event rates (per 100 patient-years and total) were generated for all endpoints. Cox regression analysis was used to adjust comparisons for potential confounders.[@R3] Hazard ratios (HRs; 95% confidence intervals (CIs)) and Wald χ^2^ tests were generated for all three pairwise comparisons: (1) AS versus MR or AR; (2) AS versus no SVD and (3) MR or AR versus no SVD.

The efficacy analyses used the intention-to-treat population and the time period to site notification. The safety endpoint analyses used the safety population and the on-treatment period (ie, time to last exposure plus 2 days). The same covariates were used as reported ([@R3]; see online supplementary material). For treatment comparisons among subgroups, event rates were summarised by treatment among AS, MR or AR, and no SVD. After adding interaction terms AS\*rivaroxaban and other-SVD\*rivaroxaban, a single overall test was performed in each model to determine treatment effect differences among the three groups; if significant, then rivaroxaban versus warfarin HRs (95% CI) were generated for all three subgroups. For each model, the proportional hazards assumption was tested and found to have been met.

All statistical analyses were performed by the Duke Clinical Research Institute (Durham, North Carolina, USA) using SAS software (V.9.2, SAS Institute, Cary, North Carolina, USA).

Results {#s3}
=======

Clinical characteristics of patients {#s3a}
------------------------------------

[Tables 1](#HEARTJNL2015308120TB1){ref-type="table"} and [2](#HEARTJNL2015308120TB2){ref-type="table"} show the location of valve disease and clinical characteristics of 1940 intention-to-treat patients. Compared with others, patients with AS were older, slightly heavier, less often had persistent AF, more new onset AF, more peripheral artery disease, prior myocardial infarction, slightly higher CHADS~2~ (C, Congestive heart failure; H, Hypertension; A, Age ≥75 years; D, Diabetes mellitus; S~2~, prior Stroke or transient ischaemic attack (TIA) or thromboembolism) score and lower creatinine clearances.

###### 

Baseline clinical characteristics for all ITT patients with known location of valve disease grouped by the three patient subgroups

  Variable                                 AS\* (n=214)     MR or AR\* (n=1726)   No SVD\* (n=12 179)   p Value†
  ---------------------------------------- ---------------- --------------------- --------------------- ----------
  Age                                      78 (73, 82)      74 (67, 79)           72 (65, 78)           \<0.0001
  Female                                   37% (79)         40% (682)             40% (4820)            0.73
  Atrial fibrillation                                                                                   0.0082
   Persistent                              79% (170)        83% (1435)            81% (9832)            
   Paroxysmal                              17% (37)         16% (277)             18% (2173)            
   New onset                               3% (7)           1% (14)               1% (174)              
  CHADS~2~ score (mean (SD))               3.6 (0.9)        3.5 (1.0)             3.5 (0.9)             0.053
  CHADS~2~ score                                                                                        
   2                                       8% (18)          14% (247)             13% (1585)            
   3                                       42% (89)         43% (743)             44% (5311)            
   4                                       33% (70)         27% (467)             29% (3521)            
   5                                       14% (30)         13% (230)             13% (1532)            
   6                                       3% (7)           2% (39)               2% (230)              
  HAS-BLED score (mean (SD))               3.0 (0.9)        2.8 (1.0)             2.8 (0.9)             0.0005
  Presenting characteristics                                                                            
   BMI, kg/m^2^                            29 (26, 32)      28 (25, 31)           28 (25, 32)           \<0.0001
   Systolic BP, mm Hg                      130 (120, 142)   130 (120, 140)        130 (120, 140)        \<0.0001
   Diastolic BP, mm Hg                     78 (70, 85)      80 (70, 85)           80 (70, 86)           \<0.0001
   Creatinine clearance,‡ ml/min           61 (44, 78)      63 (49, 80)           68 (53, 88)           \<0.0001
  Baseline comorbidities                                                                                
   Prior stroke, TIA or non-CNS embolism   46% (99)         48% (829)             56% (6806)            \<0.0001
   PAD                                     15% (32)         7% (124)              6% (672)              \<0.0001
   Hypertension                            92% (197)        89% (1542)            91% (11 049)          0.14
   Diabetes                                43% (92)         40% (690)             40% (4849)            0.64
   Prior MI                                30% (64)         23% (404)             16% (1964)            \<0.0001
   Congestive HF                           65% (139)        71% (1228)            61% (7449)            \<0.0001
   COPD                                    19% (40)         14% (243)             10% (1194)            \<0.0001
  Medications                                                                                           
   Prior vitamin K antagonist use          74% (158)        72% (1251)            61% (7409)            \<0.0001
   Prior chronic ASA use                   37% (80)         34% (589)             37% (4494)            0.079
   ACE-inhibitor/ARB at baseline           78% (167)        76% (1306)            74% (9029)            0.18
   β blocker at baseline                   65% (140)        71% (1225)            64% (7789)            \<0.0001
   Digitalis at baseline                   41% (88)         44% (754)             38% (4589)            \<0.0001
   Diuretic at baseline                    75% (160)        70% (1212)            58% (7031)            \<0.0001
  Randomised to rivaroxaban                49% (105)        48% (834)             50% (6119)            0.32

All other abbreviations can be found in [table 1](#HEARTJNL2015308120TB1){ref-type="table"}.

\*Continuous variables are shown as median (25th, 75th percentile) except where noted, and categorical variables as % (n).

†p Values are for any differences across groups.

‡Cockroft-Gault.

A, Age ≥75 years; ARB, angiotensin receptor blocker; AS, aortic stenosis; ASA, acetylsalicylic acid, aspirin; HAS-BLED, hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international normalized ratio, elderly (\> 65 years), drugs/alcohol concomitantly; BMI, body mass index; BP, blood pressure; CHADS~2~, C, congestive heart failure; CNS, central nervous system; COPD, chronic obstructive pulmonary disease; D, diabetes mellitus; H, hypertension; HF, heart failure; MI, myocardial infarction; MR or AR, mitral or aortic regurgitation; PAD, peripheral artery disease; S~2~, prior Stroke or TIA or thromboembolism; SD, standard deviation; SVD, significant valve disease; TIA, transient ischaemic attack; R, rivaroxaban; W, warfarin.

Efficacy and safety endpoints {#s3b}
-----------------------------

Event rates for efficacy and safety outcomes are presented in [figures 1](#HEARTJNL2015308120F1){ref-type="fig"} and [2](#HEARTJNL2015308120F2){ref-type="fig"}, [table 3](#HEARTJNL2015308120TB3){ref-type="table"} and in online supplementary figures 1 and 2. Stroke or systemic embolism occurred about twice as often in the AS group (4.21) than in the MR or AR (2.01) or the no SVD groups (2.09 events/100 patient-years; p\<0.05 each), whereas there was no difference between patients with MR or AR and patients with no SVD. The composite of stroke, systemic embolism or vascular death was increased approximately twofold in patients with AS (AS 10.84) compared with patients with MR or AR (4.54) and patients with no SVD (4.31 events per 100 patient-years, p\<0.01 each), whereas again, MR or AR and no SVD did not differ. All-cause death (AS 11.22, MR or AR 4.90 and no SVD 4.39 events per 100 patient-years) and the combined outcome of stroke, systemic embolism and vascular death (with or without myocardial infarction) occurred also twice as often in AS than in the other two groups (p\<0.01 for each comparison), whereas MR or AR did not differ from no SVD ([table 3](#HEARTJNL2015308120TB3){ref-type="table"}B).

###### 

Efficacy (ITT population) and safety endpoints (on-treatment population) by SVD subtype and for patients with no SVD

  \(A\) Event rates                                                                                      
  ----------------------------------------- ----------------------------- ------------------------------ -------------------------------
  Efficacy outcomes                                                                                      
   Stroke or SE                             4.21 (1.89 to 6.53) (17)      2.01 (1.50 to 2.52) (69)       2.09 (1.89 to 2.29) (487)
   Stroke, SE, or vascular death            10.84 (7.23 to 14.45) (41)    4.54 (3.78 to 5.30) (152)      4.31 (4.03 to 4.59) (982)
   Stroke, SE, vascular death, or MI        12.09 (8.25 to 15.93) (45)    5.72 (4.86 to 6.58) (189)      4.99 (4.68 to 5.30) (1128)
   Stroke                                   3.68 (1.52 to 5.84) (15)      1.71 (1.24 to 2.18) (59)       1.96 (1.77 to 2.15) (458)
   Early study drug discontinuation (%)\*   58.4 (51.5 to 65.1) (125)     39.6 (37.3 to 41.9) (685)      34.0 (33.2 to 34.8) (4161)
   Stroke per-protocol on-treatment^\*^     4.30 (1.81 to 6.79) (12)      1.50 (1.04 to 1.96) (39)       1.90 (1.70 to 2.10) (354)
   All-cause death                          11.22 (7.65 to 14.79) (43)    4.90 (4.12 to 5.68) (164)      4.39 (4.11 to 4.67) (1002)
  Safety outcomes                                                                                        
   Major or NMCR bleeding                   24.36 (18.14 to 30.58) (59)   17.66 (15.98 to 19.34) (422)   14.16 (13.60 to 14.72) (2431)
   Major bleeding                           7.61 (4.35 to 10.87) (21)     4.86 (4.03 to 5.69) (131)      3.27 (3.01 to 3.53) (625)
   Gastrointestinal bleeding                2.90 (0.89 to 4.91) (8)       2.12 (1.57 to 2.67) (57)       1.32 (1.16 to 1.48) (252)
   Intracranial haemorrhage                 1.40 (0.03 to 2.77) (4)       0.76 (0.43 to 1.09) (21)       0.59 (0.48 to 0.70) (114)

  \(B\) Group comparisons                                                                 
  ----------------------------------- ------------------------- ------------------------- -------------------------
  Efficacy outcomes                                                                       
   Stroke or SE                       1.82 (1.10 to 3.01)\*     1.87 (1.08 to 3.23)\*     0.97 (0.75 to 1.26)
   Stroke, SE or vascular death       2.03 (1.47 to 2.79)\*\*   2.12 (1.49 to 3.01)\*\*   0.96 (0.80 to 1.14)
   Stroke, SE, vascular death or MI   1.91 (1.41 to 2.59)\*\*   1.84 (1.32 to 2.56)\*\*   1.04 (0.88 to 1.21)
   Stroke                             1.70 (1.00 to 2.92)\*     1.93 (1.07 to 3.46)\*     0.88 (0.67 to 1.16)
   All-cause death                    1.88 (1.38 to 2.56)\*\*   1.94 (1.38 to 2.72)\*\*   0.97 (0.82 to 1.15)
  Safety outcomes                                                                         
   Major or NMCR bleeding             1.28 (0.98 to 1.66)       1.14 (0.87 to 1.51)       1.12 (1.00 to 1.24)\*
   Major bleeding                     1.61 (1.03 to 2.49)\*     1.24 (0.78 to 1.97)       1.30 (1.07 to 1.57)\*\*
   Gastrointestinal bleeding          1.39 (0.68 to 2.83)       1.04 (0.49 to 2.18)       1.34 (1.00 to 1.80)\*
   Intracranial haemorrhage           2.04 (0.75 to 5.60)       1.63 (0.55 to 4.77)       1.26 (0.79 to 2.01)

\*Although early study drug discontinuation rates were different in the three groups, event rates for stroke were not markedly different between on-treatment and ITT patients.

Event rates are underadjusted.

p Values for group comparisons: \*p\<0.05, \*\*p\<0.01.

AS, aortic stenosis; CI, confidence interval; ITT, intention to treat; MI, myocardial infarction; MR or AR, mitral or aortic regurgitation; NMCR, non-major clinically relevant; pt-years, patient-years; SE, systemic embolism; SVD, significant valve disease.

![Efficacy endpoints by SVD subtype and for patients with no SVD based on ITT patients. Efficacy endpoints (events per 100 patient-years, unadjusted) by SVD subtype and for patients with no SVD based on ITT patients. p Values for any difference among groups are based on Cox proportional hazards models. Patients in both treatment arms are combined. For results of detailed statistical analyses, see [table 3](#HEARTJNL2015308120TB3){ref-type="table"}. ITT, intention to treat; MI, myocardial infarction; pt-years, patient-years; SE, systemic embolism; SVD, significant valve disease; MR or AR, mitral or aortic regurgitation; vasc. death, vascular death.](heartjnl-2015-308120f01){#HEARTJNL2015308120F1}

![Safety endpoints by SVD subtype and for patients with no SVD. Safety endpoints (events per 100 patient-years, unadjusted) by SVD subtype and for patients with no SVD. p Values for any difference among groups are based on Cox proportional hazards models. Patients in both treatment arms are combined. For results of detailed statistical analyses, see [table 3](#HEARTJNL2015308120TB3){ref-type="table"}. NMCR, non-major clinically relevant; pt-years, patient years; SVD, significant valve disease; MR or AR, mitral or aortic regurgitation.](heartjnl-2015-308120f02){#HEARTJNL2015308120F2}

Early study drug discontinuation rates were different in the three groups (AS 58%, MR or AR 40% and no SVD 34%). However, patterns of stroke rates in the per-protocol on-treatment population were not markedly different from those in intention-to-treat patients ([table 3](#HEARTJNL2015308120TB3){ref-type="table"}A).

Major bleeding ([figure 2](#HEARTJNL2015308120F2){ref-type="fig"} and [table 3](#HEARTJNL2015308120TB3){ref-type="table"}B, see online supplementary figure S2) occurred more frequently in AS (7.61) than in no SVD (3.27 events/100 patient-years; adjusted HR 1.61, CI 1.03 to 2.49, p\<0.05). In patients with MR or AR, the risk of major bleeding was also significantly higher (4.86 events/100 patient-years) than in no SVD (adjusted HR 1.30, CI 1.07 to 1.57, p\<0.01), whereas the difference between AS and MR or AR did not reach significance (adjusted HR 1.24, CI 0.78 to 1.97). Major clinically relevant and NMCR bleeding occurred more often in AS (24.36), less often in MR or AR (17.66) and was lowest in no SVD (14.16 events/100 patient-years). However, only the difference between MR or AR and no SVD reached significance (p\<0.05). Gastrointestinal bleeding rates were numerically higher in AS and MR or AR, but statistically different only for MR or AR versus no SVD (p\<0.05). Intracranial haemorrhage occurred rarely and did not differ among groups ([table 3](#HEARTJNL2015308120TB3){ref-type="table"}B).

Treatment comparisons for efficacy and safety endpoints {#s3c}
-------------------------------------------------------

There were no significant interactions among patients randomised to rivaroxaban and warfarin, indicating a consistent risk relationship between rivaroxaban and warfarin across the three subgroups for all efficacy endpoints (see online supplementary table S1). For the major or NMCR bleeding and major bleeding outcomes, the interaction tests were significant ([figure 3](#HEARTJNL2015308120F3){ref-type="fig"}, see online supplementary table S1). In patients without SVD, rivaroxaban and warfarin had a neutral relationship (HRs very close to 1), while patients with MR or AR had an elevated risk of either of these two bleeding categories with rivaroxaban compared with warfarin (HR 1.32 and 1.63, respectively). Patients with AS also had HRs of 1.18 and 1.73, but the CIs were wide, reaching 1.0. There was no significant interaction for gastrointestinal bleeding, and there were too few intracranial haemorrhages to draw any conclusions (see online supplementary table S1).

![Treatment comparisons between patients allocated to rivaroxaban and warfarin. Treatment comparisons between patients allocated to rivaroxaban and warfarin for safety endpoints among SVD subtypes and for patients with no SVD. Events per 100 patient-years, unadjusted. p Values for any difference among groups are based on Cox proportional hazards models. Patients in each treatment are shown separately. For results of detailed statistical analyses, see online [supplementary table](http://dx.doi.org/10.1136/heartjnl-2015-308120) S1. NMCR, non-major clinically relevant; pt-years, patient years; SVD, significant valve disease; MR or AR, mitral or aortic regurgitation.](heartjnl-2015-308120f03){#HEARTJNL2015308120F3}

Discussion {#s4}
==========

In ROCKET AF, 14.1% of patients had SVD that did not meet mitral stenosis and artificial valve prostheses exclusion criteria[@R3]; these patients were older and had more comorbidities than those without SVD, similar to preliminary data from the Randomised Evaluation of Long Term Anticoagulant Therapy (RE-LY) and Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trials.[@R4] In ROCKET AF, the rates of stroke or systemic embolism were comparable among patients with and without SVD, whereas the rates of major or NCMR or major bleeding alone were higher in patients with SVD,[@R3] similar to findings from ARISTOTLE[@R4] [@R5] and RE-LY.[@R4] [@R6] In patients with SVD allocated to rivaroxaban, the rates of major and NMCR or major bleeding alone were higher than in warfarin patients compared with no-SVD patients. However, there was no difference between both treatment arms after controlling for risk factors and potential confounders. For intracranial haemorrhage, there was no interaction between patients with and without SVD where the overall rate was lower among those randomised to rivaroxaban.[@R3] Our patients with SVD[@R3] were older (median 75 vs 71 years), had higher CHADS~2~ scores (mean 3.5 vs 2.2) and had more frequently prior stroke, systemic embolism or TIA (48.2% vs 18.8%) than patients with valvular heart disease in ARISTOTLE.[@R5]

Preliminary data for our retrospective exploratory analysis were recently presented.[@R7] Here, we present a detailed analysis of valve disease subgroups in patients with non-valvular AF treated with oral anticoagulation.

Clinical characteristics {#s4a}
------------------------

Due to protocol inclusion and exclusion criteria,[@R1] [@R2] patients with AS suffered moderate-to-intermediate aortic lesions since severe lesions requiring imminent intervention were excluded. The majority of patients in the AS group (59%) also had MR or AR ([table 1](#HEARTJNL2015308120TB1){ref-type="table"}). No reasonable comparison can be made between our patients (who constitute a special group, all with AF requiring anticoagulation for the prevention of stroke or systemic embolism) with other reports.[@R8] These reports either included patients with aortic valve sclerosis,[@R8] or AS without any anticoagulation,[@R9] or patients with MR selected on the basis of left ventricular dysfunction who had a low prevalence of AF of 8--11%[@R10] or 8.8--16.3%[@R11] without any information on oral anticoagulation or no information on the prevalence of AF or oral anticoagulation.[@R12]

Efficacy outcomes {#s4b}
-----------------

Our analysis suggests that secondary endpoints, including all-cause death, were significantly higher among AS patients, despite AS being of moderate or intermediate severity. Also, stroke and systemic embolism (the primary outcome parameter) occurred about twice as often in patients with AS compared with those without ([table 3](#HEARTJNL2015308120TB3){ref-type="table"}).

Clinical outcomes like stroke, systemic embolism or death among patients with valvular disease subtypes treated with oral anticoagulation have not been well established. The association between AS and stroke is controversial.[@R13] The need for oral anticoagulation in patients with AS is generally not mentioned in valvular heart disease guidelines,[@R14] [@R17] except when AF is present.

The rate of stroke in the AS group with AF on oral anticoagulation was high (3.68/100 patient-years) in comparison with the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial in which patients in the early phase of disease were selected for drug intervention (0.56/100 patient-years).[@R9] SEAS only included patients not on oral anticoagulation; only 6.4% had AF. SEAS patients had mild-to-moderate AS (presumably similar in severity to our patients), but a much lower stroke risk, which correlated to a low CHA~2~DS~2~-VASc (C, congestive heart failure; H, hypertension; A, age ≥75 years; D, diabetes mellitus; S~2~, prior Stroke or TIA or thromboembolism; V, vascular disease; A, age 65--74 years; SC, sex category (female)) score of 1.8±1.2.[@R9] In our study, patients were markedly older (78 median vs 67.3±9.7 years), and all had AF and a 3.6 CHADS~2~ score (median). Therefore, the higher rate of stroke and systemic embolism in our cohort compared with SEAS[@R9] may be explained by the presence of AF, older age and other risk factors impacting the stroke risk score.

In a study from Olmsted County,[@R18] 22% of patients with AS experienced a cerebrovascular event during 7-year follow-up (adjusted yearly risk 3.1%), which seems comparable to ROCKET AF. Yet, the Olmsted County analysis excluded systemic embolism and included patients with severe AS (39% of cases); 48% received oral anticoagulation. Following adjustment for age and AF, severe AS (compared with moderate) was associated with an increased risk of cerebrovascular events (risk ratio 5.35, 95% CI 1.4 to 8.6).[@R18]

The death rate in patients with AS was about twice as high as those with MR or AR and no SVD (p\<0.01 each). In the Olmsted County study,[@R18] patients with AS had increased mortality (57% at 5 years; 71% at 7 years), which is not too different from our death rate (11.22/100 patient-years) when compared with their 5-year and 7-year rates. Nevertheless, as previously noted, the Olmsted County study also included patients with severe AS, who have a 50% 1-year mortality rate.

MR was the dominant diagnosis in the MR or AR group. The risk of stroke or systemic embolism in patients with MR or AR was comparable with no SVD. Some reports suggest that patients with AF with MR have lower rates of left atrial thrombi intra-operatively[@R19] [@R20] or on echocardiography[@R21] than those without MR. Some suggest a reduced propensity to thromboembolism in patients with MR and AF,[@R22] although other studies failed to show a similar beneficial effect of MR.[@R25] In patients with non-rheumatic AF, Miyasaka *et al*[@R24] observed the highest prevalence of thromboembolism (28%) in those with grade 1 MR, whereas those with grade [\>]{.ul}2 (8%, p=0.006) and with none had the lowest event rates (11%, p=0.007). Platelet activation due to MR may enhance the formation of platelet--fibrin thrombus on the mitral leaflet, thereby increasing embolisation.[@R26]

In contrast to some of the reports mentioned above, we could not confirm a reduced thromboembolism rate in our patients with MR compared with no SVD.

Safety outcomes {#s4c}
---------------

Current literature lacks detailed analyses of bleeding in valve disease patients taking oral anticoagulants to prevent stroke. In our study, patients with AS had the highest risk of major bleeding in comparison with patients with no SVD (p\<0.05) but not significantly higher compared with patients with MR or AR. The latter patients also had a significantly higher rate of major bleeding than patients with no SVD (p\<0.01).

Our major bleeding rate of 3.27 events per 100 patient-years in patients with no SVD ([table 3](#HEARTJNL2015308120TB3){ref-type="table"}) is close to real-world data from a pharmacovigilance study of rivaroxaban with non-valvular AF that excluded patients with any type of valve disease. In this study of 27 467 patients, the incidence of major bleeding was 2.86 per 100 person-years (95% CI 2.61 to 3.13).[@R27] CHADS~2~ scores were 3.0 for those with major bleeding and 2.2 for those without; these scores are lower than those in our population.

Mechanisms of thromboembolism and of bleeding in valvular disease {#s4d}
-----------------------------------------------------------------

Potential mechanisms for systemic embolism in AS include increased mean platelet volume,[@R28] increased platelet production indices in aortic valve sclerosis patients[@R29] and turbulent flow with subsequent activation of coagulation and platelets.[@R30] Minimally calcified aortic valves have proven to exhibit anti-aggregatory effects, whereas AS does not demonstrate these same effects.[@R31] In addition to a possible prothrombotic effect, other phenomena observed in patients with AS demonstrate evidence of impaired haemostasis with a decrease in von Willebrand factor.[@R32] Concomitant AF further complicates the picture since AF is consistently related to higher levels of von Willebrand factor than in AF\'s absence.[@R33] Consequently, there may be opposing disturbances in the coagulation system due to the AS/AF combination.

We observed an increased bleeding risk in patients with AS, which was more pronounced on rivaroxaban than warfarin; if this is not a chance finding, then it is of clinical importance and needs further corroboration, yet our data do not explain the mechanisms behind the potentially higher bleeding rate in patients with AS.

Bleeding in patients with AS has been related to gastrointestinal angiodysplasia (ie, Heyde\'s syndrome),[@R37] which is associated with acquired type 2A von Willebrand syndrome (characterised by the loss of the largest multimers of von Willebrand factor).[@R41] [@R42] Shear stress ex vivo enhances the proteolysis of von Willebrand factor in normal plasma.[@R42] Vincentelli *et al*[@R32] found von Willebrand factor abnormalities to be directly related to the stenosis severity; furthermore, they could be reversed by aortic valve replacement if there was no implanted prosthesis mismatch.[@R32] [@R43]

Effect of type of anticoagulation {#s4e}
---------------------------------

For efficacy outcomes, there were no significant interactions since the interaction tests between treatment and SVD group were non-significant; therefore, the risk relationship between rivaroxaban and warfarin was consistent across SVD subgroups. HRs from the full ROCKET AF cohort[@R2] are the best estimate of treatment effects.

Interaction tests for between-treatment bleeding suggested a significant difference when comparing the three subgroups. In patients without SVD, rivaroxaban and warfarin had a neutral relationship (HR close to 1.0), whereas those with MR or AR had an elevated risk of any bleeding (except for intracranial haemorrhage) with rivaroxaban compared with warfarin. Patients with AS also had higher HR for rivaroxaban versus warfarin, which was especially pronounced for major bleeding (this difference did not reach statistical significance; CIs were below and above 1.0). There was a tendency towards higher rates of gastrointestinal bleeding in patients with AS and MR or AR. There were too few intracranial haemorrhages to draw any conclusions.

Our study had several limitations. First, although we examined a large trial population, the proportion of patients with moderate or intermediate AS severity was relatively small. Second,[@R3] the protocol did not include a precise quantification of valve disease, so the two SVD subgroups do not represent isolated disease types (eg, patients in the AS group also had regurgitant lesions). Third, our data do not allow any balance estimate between AS severity and other lesions (if present). Finally, the relatively low number of cases, especially in those with AS, reduces the chance of finding true differences. Therefore, conclusions regarding treatment effects should be drawn cautiously. More studies are needed to better understand the thromboembolic event-related clinical characteristics and outcomes in patients with valvular disease (after exclusion of mitral stenosis or artificial valves).

Conclusions {#s5}
===========

Our retrospective exploratory analysis of ROCKET AF found that among patients with AF treated with oral anticoagulation (either rivaroxaban or warfarin), AS stood out from other groups with regard to efficacy endpoints (eg, stroke, systemic embolism and vascular death); in patients with other valve disease (MR or AR) and non-valve disease (no SVD), these endpoints did not differ. Major bleeding rates increased from no SVD to MR or AR to AS. Oral anticoagulation type did not cause a difference in efficacy outcomes, but bleeding occurred more frequently in patients with AS and other types of valve disease randomised to rivaroxaban rather than warfarin (although the difference missed significance). There was no difference in the no SVD group between treatment allocation. We believe our study is the first to suggest that in patients with AF who mainly have AS treated with oral anticoagulation, the efficacy and safety outcomes may be different from those with MR or AR (predominantly MR) or no SVD. This notion may be intuitive, but has not been demonstrated in a patient population selected for AF presence. Key messagesWhat is already known on this subject?Current literature is lacking detailed analyses of various types of valve disease (after exclusion of patients with mitral stenosis or artificial prostheses) in the presence of atrial fibrillation with regard to systemic embolism and bleeding when a patient is on warfarin or rivaroxaban for stroke prevention.What might this study add?In this first detailed analysis of subgroups with valve disease, the composite of stroke, systemic embolism or vascular death was about twofold higher in aortic stenosis (AS) than in mitral or aortic regurgitation or no valve disease. Major bleeding occurred more frequently in AS than in the other two groups. For efficacy endpoints comparing rivaroxaban and warfarin, there were no significant treatment interactions but for bleeding outcomes, the interaction tests were significant.How might this impact on clinical practice?We found that patients with atrial fibrillation and AS who are being treated with oral anticoagulation have efficacy and safety outcomes that are distinctly different from patients with other types or without any significant valve disease; this finding should encourage clinicians to carefully consider the risks of thromboembolic complications versus bleeding especially in patients with AS.
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